（记者 曾健辉） 每经头条（nbdtoutiao）——"为了孩子吃上饭，自己只能靠喝水撑着"！美政府停摆危机逼近"临界 点"，4200万人吃饭成问题 每经AI快讯，南新制药11月3日晚间发布公告称，截至2025年10月31日，公司通过上海证券交易所交易 系统以集中竞价交易方式累计回购公司股份约36万股，占公司总股本约2.74亿股的比例为0.13%，回购 成交的最高价为7.97元/股，最低价为7.02元/股，支付的资金总额为人民币约270万元。 ...

重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 357,179股 | | 累计已回购股数占总股本比例 | 0.13% | | 累计已回购金额 | 2,696,235.78元 | | 实际回购价格区间 | 7.02元/股~7.97元/股 | 证券代码：688189 证券简称：南新制药 公告编号：2025-051 湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 10 月，公司通过上海证券交易所交易系统以集中竞价交易方式回购公 司股份 91,663 股，占公司总股本 274,400,000 股的比例为 0.03% ...

Core Insights - Nanjing Pharmaceutical focuses on antiviral and major disease treatment drug research and development, with strong technical capabilities in the prevention and treatment of infectious diseases like influenza [1] Financial Performance - For Q3 2025, Nanjing Pharmaceutical reported revenue of 83.15 million yuan, ranking 106th among 110 companies in the industry, significantly lower than the industry leader, East China Pharmaceutical, which reported 32.664 billion yuan [2] - The company's net profit was -75.78 million yuan, ranking 90th in the industry, far behind the top performers, Heng Rui Pharmaceutical at 5.76 billion yuan and Fosun Pharmaceutical at 3.056 billion yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 22.57%, an increase from 11.61% in the same period last year, but still below the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 33.44%, a significant decline from 60.76% in the previous year and below the industry average of 57.17% [3] Executive Compensation - The chairman and general manager, Zhang Shixi, received a salary of 735,500 yuan in 2024, a decrease of 272,700 yuan from 1,008,200 yuan in 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 49.13% to 14,100, while the average number of circulating A-shares held per shareholder decreased by 32.95% to 19,400 [5] - New major shareholders include several funds from GF Fund Management, with notable holdings of 5.4741 million shares, 5.3492 million shares, 3.8594 million shares, and 1.5945 million shares [5]

格隆汇10月30日丨南新制药(688189.SH)发布三季报，2025年前三季度实现营业总收入8315.44万元，同 比下降66.89%；归属母公司股东净利润-6863.38万元，较上年同期亏损增加1141.79万元；基本每股收益 为-0.2501元。 ...

Financial Performance - The company's operating revenue for the third quarter was ¥21,308,086.94, a decrease of 40.45% compared to the same period last year[3]. - The total profit for the third quarter was -¥32,149,686.43, with a year-to-date total profit of -¥76,118,300.93, reflecting significant losses[3]. - The net profit attributable to shareholders for the third quarter was -¥28,631,491.51, down from -¥67,388,600.15 in the previous year[3]. - Total operating revenue for the first three quarters of 2025 was CNY 83,154,434.61, a decrease of 66.9% compared to CNY 251,110,585.69 in the same period of 2024[19]. - Net loss for the first three quarters of 2025 was CNY 75,777,289.57, compared to a net loss of CNY 65,925,432.36 in the same period of 2024, indicating a worsening of 14.1%[20]. - The basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.2501, compared to CNY -0.2089 in 2024, indicating a decline in earnings performance[21]. Research and Development - Research and development expenses totaled ¥9,746,614.10 for the third quarter, a decrease of 61.66% year-over-year, with R&D expenses accounting for 45.74% of operating revenue[3]. - Research and development expenses for the first three quarters of 2025 were CNY 27,300,905.81, slightly up from CNY 26,325,369.38 in 2024, representing an increase of 3.7%[20]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥75,223,063.51, an increase of 149.83% compared to the previous year[3]. - Cash received from sales of goods and services in the first three quarters of 2025 was CNY 186,545,063.10, down from CNY 257,971,161.66 in 2024, a decrease of 27.6%[23]. - Cash received from other operating activities was $18,955,390.12, up from $12,103,123.17, indicating improved operational cash generation[24]. - The ending cash and cash equivalents balance was $422,663,108.40, compared to $388,506,660.17 previously, showing a slight increase in liquidity[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,033,888,431.00, a decrease of 15.42% from the previous year-end[4]. - The total liabilities decreased from CNY 344,132,614.55 in 2024 to CNY 233,328,012.55 in 2025, a reduction of 32.2%[16]. - The total equity attributable to shareholders decreased from CNY 936,592,121.87 in 2024 to CNY 865,990,145.96 in 2025, a decline of 7.5%[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 14,114[8]. - Hunan Pharmaceutical Development Investment Group Co., Ltd. holds 28.57% of shares, totaling 78,400,000 shares[9]. - The company has repurchased a total of 265,516 shares, representing 0.10% of the total share capital, with a total expenditure of RMB 1,967,393.92[11]. Market Conditions - The company is currently facing increased market competition, which has significantly impacted sales and revenue[6]. Accounting and Reporting - The company identified an accounting error that reduced 2023 revenue by ¥24,539,700, representing 3.4% of total revenue for that year[4]. - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[26].

证券代码：688189 证券简称：南新制药 公告编号：2025-049 一、募集资金基本情况 根据中国证监会于 2020 年 2 月 25 日出具的《关于同意湖南南新制药股份有 限公司首次公开发行股票注册的批复》（证监许可[2020]318 号），同意湖南南新 制药股份有限公司（以下简称"公司"）首次公开发行股票的注册申请。公司首 次公开发行人民币普通股 3,500 万股，发行价格为 34.94 元/股，募集资金总额 为人民币 122,290.00 万元，扣除发行费用合计人民币 8,761.77 万元（不含增值 税）后，实际募集资金净额为人民币 113,528.23 万元。上述募集资金已于 2020 年 3 月 20 日全部到位，由天职国际会计师事务所（特殊普通合伙）对本次发行 募集资金的到账情况进行了审验，并出具了（天职业字[2020]16008 号）《验资 报告》。 湖南南新制药股份有限公司 关于使用部分闲置募集资金临时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 临时补流募集资金 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-050 湖南南新制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 3 日（星期一）至 11 月 9 日（星期日）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过湖南南新制药股份 有限公司（以下简称"公司"）邮箱 nanxin@nucien.com 进行提问。公司将在说 明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）披 露了公司《2025 年第三季度报告》。为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果和财务状况，公司计划于 2025 年 11 月 10 日（星期一） 9:00-10:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 20 ...

西部证券股份有限公司 关于湖南南新制药股份有限公司 使用部分闲置募集资金临时补充流动资金的核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为湖南南新制 药股份有限公司（以下简称"南新制药"或"公司"）首次公开发行股票并在科创 板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则（2025年4月修订）》《上市公司募集资金监管规则》《上海证券交易 所科创板上市公司自律监管指引第1号——规范运作（2025年5月修订）》以及《上海 证券交易所上市公司自律监管指引第11号——持续督导 （2025年3月修订）》等相关 规定履行持续督导职责，对南新制药拟使用闲置募集资金临时补充流动资金事项进 行了核查，核查情况及核查意见如下： 一、募集资金基本情况 | 发行名称 | 2020 | | 年首次公开发行股份 | | | --- | --- | --- | --- | --- | | 募集资金总额 | 122,290.00 | | 万元 | | | 募集资金净额 | 113,528.23 | | 万元 | | | 募集资金到账时间 | 2020 年 | 3 | 月 20 | ...

Core Insights - Nanjing Pharmaceutical experienced a 5.23% increase in stock price, reaching 8.86 CNY per share, with a trading volume of 15.72 million CNY and a market capitalization of 2.43 billion CNY [1] Company Overview - Hunan Nanjing Pharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, established on December 27, 2006, and listed on March 26, 2020. The company focuses on the research, production, and sales of antiviral and infectious disease prevention drugs, as well as treatments for major diseases like cardiovascular diseases and diabetes. Its main business revenue is derived entirely from chemical drug formulations, accounting for 100% [1] Shareholder Information - Dazhong Fund's Dazhong Jingheng Mixed A (090019) is among the top ten circulating shareholders of Nanjing Pharmaceutical, holding 2.9738 million shares, unchanged from the previous period, representing 1.08% of circulating shares. The estimated floating profit today is approximately 1.3085 million CNY [2] Fund Performance - Dazhong Jingheng Mixed A (090019) was established on June 15, 2012, with a latest scale of 397 million CNY. Year-to-date returns are 39.82%, ranking 1849 out of 8226 in its category. Over the past year, returns are 52.22%, ranking 848 out of 8099, and since inception, returns have reached 369.48% [2] Fund Manager Information - The fund manager of Dazhong Jingheng Mixed A (090019) is Su Bingyi, who has a cumulative tenure of 13 years and 265 days. The total asset scale of the fund is 1.24 billion CNY, with the best fund return during his tenure being 245.86% and the worst being -71.74% [3] Fund Holdings - Dazhong Jingheng Mixed A (090019) has Nanjing Pharmaceutical as its second-largest holding, with 2.9738 million shares, unchanged from the previous period, representing 2.67% of the fund's net value. The estimated floating profit today is approximately 1.3085 million CNY [4]

Core Insights - The chemical products sector experienced a slight increase of 0.11% on October 24, with Boyuan Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Sector Performance - Boyuan Co., Ltd. (301617) closed at 102.79, with a significant increase of 14.34% and a trading volume of 91,000 shares, resulting in a transaction value of 902 million yuan [1] - Yahua Group (002497) saw a rise of 10.03%, closing at 17.88 with a trading volume of 1.2768 million shares [1] - Licheng Industrial (001218) increased by 6.97%, closing at 23.78 with a trading volume of 95,700 shares [1] - Guangdong Hongda (002683) rose by 4.77%, closing at 39.94 with a trading volume of 237,200 shares [1] - Other notable performers include Shengda Biological (603079) up 4.29%, Jianlong Micro-Nano (688357) up 4.04%, and Gaodian New Materials (300200) up 3.86% [1] Capital Flow - The chemical products sector saw a net outflow of 291 million yuan from main funds, while retail investors contributed a net inflow of 379 million yuan [1]